Genmab and CureVac Collaborate to Develop mRNA-based Antibody Therapeutics

 Genmab and CureVac Collaborate to Develop mRNA-based Antibody Therapeutics

Genmab and CureVac Collaborate to Develop mRNA-based Antibody Therapeutics

Shots:

  • CureVac to receive $10M upfront, $22.2M equity investment, milestones and royalties on sales of the first product. The companies jointly develop the first program while Genmab to get an option to initiate an additional three programs during 5yrs. research term
  •  CureVac will be responsible to develop first product up to IND, after that Genmab will develop and commercialize the initial product. If Genmab exercises the option, CureVac will receive b/w $275M to $368M as milestone and royalties/product
  • Additionally, CureVac has an option to participate in the development & commercialization of one additional program. The collaboration will utilize CureVac’s mRNA technology with Genmab’s Ab technologies and expertise

Click here ­to­ read full press release/ article | Ref: Genmab | Image: CureVac

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post